Key result
Novel type 2 oral poliovirus vaccines nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2-specific intestinal neutralizing responses in 40.0% and 46.7% of healthy adults, respectively.
Why the study?
Do novel live attenuated type 2 oral poliovirus vaccines induce intestinal antibody responses in healthy adults?
RCT (n=30)
Blinded
No
Do novel live attenuated type 2 oral poliovirus vaccines induce intestinal antibody responses in healthy adults?
Answers are grounded in this paper and cite their sources.
Both novel live attenuated type 2 oral poliovirus vaccines induced detectable intestinal neutralizing responses in over 40% of healthy adults.
In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18-50 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (n = 15); nOPV2-c2: S2/S15domV/CpG40 (n = 15)) and isolated for 28 days in a purpose-built containment facility. Using stool samples collected near days 0, 14, 21, and 28, we evaluated intestinal neutralization and immunoglobulin A responses to the nOPV2s and found that nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2-specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively.
No takes yet. Share an insight, caveat, or question.
Brickley et al. (2020) conducted an RCT in Healthy adults (n=30). nOPV2-c1 vs. nOPV2-c2 was evaluated on detectable poliovirus type 2-specific intestinal neutralizing responses. Novel type 2 oral poliovirus vaccines nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2-specific intestinal neutralizing responses in 40.0% and 46.7% of healthy adults, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: